Health Care·Pharmaceuticals·$153.6B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $0.54 | N/A | -1.82% |
management commentary, guidance changes, and full analysis available with Pro.
| -1.82% |
Tone: Defensive
Overall, management expressed concerns about market conditions but did not offer detailed insights into future performance.
Management did not provide specific guidance for future quarters.
The company acknowledged challenges in the current market environment.
Pfizer's earnings report showed a slight miss on EPS, which contributed to a notable drop in stock price by 4.47%. The lack of revenue data and guidance may have raised concerns among investors about the company's future performance. Overall, the market reaction reflects uncertainty regarding Pfizer's upcoming quarters.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
HARTFORD INS GROUP I
Apr 29, 2013